Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sells $770,997.89 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Xenon Pharmaceuticals Stock Down 0.7 %

Shares of XENE opened at $38.63 on Friday. Xenon Pharmaceuticals Inc. has a 52-week low of $35.53 and a 52-week high of $50.99. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -13.70 and a beta of 1.19. The business’s 50 day moving average is $41.85 and its two-hundred day moving average is $40.46.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the company earned ($0.73) EPS. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on XENE. Raymond James reiterated an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright restated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $56.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 487 shares during the last quarter. Advisors Asset Management Inc. grew its position in shares of Xenon Pharmaceuticals by 3.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 13,592 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 493 shares during the last quarter. Blue Trust Inc. lifted its holdings in Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares during the last quarter. Arizona State Retirement System lifted its stake in Xenon Pharmaceuticals by 4.0% in the second quarter. Arizona State Retirement System now owns 17,949 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 688 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Xenon Pharmaceuticals by 1.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 48,946 shares of the biopharmaceutical company’s stock worth $1,908,000 after acquiring an additional 769 shares during the period. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.